Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)

Vollenweider, F.X., Leenders, K.L., Øye, I., Hell, D., Angst, J. · 1997 · European Neuropsychopharmacology

Abstract

Until recently, racemic ketamine (S-ketamine/R-ketamine = 50:50) has been used to study NMDA receptor hypofunction in relation to pathophysiological models of schizophrenia. Ketamine given to normal humans in subanesthetic doses produces a model psychosis including both positive and negative symptoms of schizophrenia. More recently it has been shown that at subanesthetic doses the pure (S)- and (R)-ketamine enantiomeres interact differently with the NMDA and sigma receptor sites in human brain. It was found that (S)-ketamine binds with a 3-4 time higher affinity to the PCP binding site of the NMDA receptor than (R)-ketamine, and that at these concentrations (R)-ketamine interacts also weakly with the sigma receptor sites, where (S)-ketamine binds only negligibly. To further investigate the role of NMDA-receptor mediated neurotransmission in schizophrenic psychosis, the effects of pure (S)- and (R)-ketamine enantiomeres on brain energy metabolism in normal humans using positron emission tomography and [18F]fluorodeoxyglucose (FDG) are reported here. Psychotomimetic doses of (S)-ketamine increased cerebral metabolic rates of glucose (CMRglu) markedly in the frontal cortex including the anterior cingulate, parietal and left sensorimotor cortex, and in the thalamus. The metabolic changes in the frontal and left temporal cortex correlated with ego-disintegration and hallucinatory phenomena. Equimolar doses of (R)-ketamine tended to decrease CMRglu across brain regions and significantly suppressed CMRglu in the temporomedial cortex and left insula. (R)-ketamine did not produce psychotic symptoms, but a state of relaxation. The (S)-ketamine-induced metabolic hyperfrontality appears to parallel similar metabolic findings in acute psychotic schizophrenic patients and encourages further investigations of glutamatergic disturbances in schizophrenia.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0924-977x(96)00042-9

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 60 references

Research works printed but not linked: 4

  1. Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie AMDP (1981) Das AMDP-System. Manual zur Dokumentation psychiatrischer Befunde. Springer-Verlag, Berlin.
  2. Bowers, M.B. and Freedman, D.X. (1966) `Psychedelic' experiences in acute psychoses. Arch. Gen. Psychiatry 15, 240–248. · DOI · Paper page
  3. Dittrich, A. (1994) Psychological aspects of altered states of consciousness of the LSD type: measurements of their basic dimensions and prediction of individuall differences. In: Pletscher, A. and Ladewig, D. (Eds.), 50 Years of LSD. Current Status and Perspectives of Hallucinogens. Parthenon Publishing, New York, pp. 101–118.
  4. Scharfetter, C. (1995) The self-experience of schizophrenics. Empirical studies of the ego/self in schizophrenia, borderline disorders and depression. Psychiatric University Hospital of Zürich, University Press (ISBN 3-9520832-1-6), Zürich.

Cited by

See all 440

Metadata

Authors
Vollenweider, F. X., Leenders, K. L., Øye, I., Hell, D., & Angst, J.
Affiliations
  • Psychiatrische Universitätsklinik Zürich (CH)
  • Paul Scherrer Institute (CH)
Corresponding author
Vollenweider, F.X.
Venue
European Neuropsychopharmacology
Publisher
Elsevier BV
Published
1997-02
Volume
7
Issue
1
Pages
25-38
ISSN
0924-977X (ISSN-L)
OpenAlex
W1991333985
Cited by
413
References
60
Citations by year
2026: 3 · 2025: 21 · 2024: 24 · 2023: 16 · 2022: 30 · 2021: 29 · 2020: 30 · 2019: 17 · 2018: 21 · 2017: 8 · 2016: 13 · 2015: 16 · 2014: 11 · 2013: 12 · 2012: 14
FWCI
4.61
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • European Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
  • DORA PSI (Paul Scherrer Institute) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Funders
Paul Scherrer Institut
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
esketamine, (R)-ketamine, ketamine enantiomers, NMDA receptor hypofunction, schizophrenia, brain glucose metabolism, frontal cortex, thalamus, sigma receptors, psychotomimetic effects, hallucinations, glutamatergic dysfunction, brain energy metabolism
MeSH terms
Adult, Brain Chemistry, Cerebral Cortex, Female, Glucose, Humans, Ketamine, Kinetics, Functional Laterality, Male, Psychiatric Status Rating Scales, Psychometrics, Psychoses, Substance-Induced, Stereoisomerism, Tomography, Emission-Computed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). https://app.cochat.ai/papers/10.1016/s0924-977x(96)00042-9
The paper
Vollenweider, F. X., Leenders, K. L., Øye, I., Hell, D., & Angst, J. (1997). Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). European Neuropsychopharmacology. https://doi.org/10.1016/s0924-977x(96)00042-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.